Email Alert RSS
Volume 7 Issue 3
May  2016
Turn off MathJax
Article Contents
Abstract
References
Ni XU, Cong-wei LIU, Fang-tian DONG. Dexamethasone Intravitreal Implant Compared with Anti-vascular Endothelial Growth Factor Injection for Macular Edema Secondary to Retinal Vein Occlusion: a Meta-analysis[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(3): 168-175. DOI: 10.3969/j.issn.1674-9081.2016.03.002
Citation: Ni XU, Cong-wei LIU, Fang-tian DONG. Dexamethasone Intravitreal Implant Compared with Anti-vascular Endothelial Growth Factor Injection for Macular Edema Secondary to Retinal Vein Occlusion: a Meta-analysis[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(3): 168-175. DOI: 10.3969/j.issn.1674-9081.2016.03.002
shu

Dexamethasone Intravitreal Implant Compared with Anti-vascular Endothelial Growth Factor Injection for Macular Edema Secondary to Retinal Vein Occlusion: a Meta-analysis

  • 1.

    Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Orthopedics, the Second Xiangya Hospital of Central South University, Changsha 410011, China

More Information
  • Corresponding author:

    DONG Fang-tian Tel: 010-69156360, E-mail: d_fangtian@sina.com

  • Received Date: January 12, 2016
  • Issue Publish Date: May 29, 2016
    Graphical Abstract
    • Abstract
  •   Objective  To compare the efficacy and safety of intravitreal injections of dexamethasone implants (DEX) with anti-vascular endothelial growth factor (VEGF) in the treatment of macular edema (ME)secondary to retinal vein occlusion (RVO).
      Methods  The databases of Cochrane Library, PubMed, EMBASE, Ovid Medline, and ClinicalTrial.gov between January 1948 and June 2015 were searched for studies comparing DEX with anti-VEGF for the treatment of ME caused by RVO with key words "retinal vein occlusion", "macular edema", "anti-VEGF", "pegaptanib", "Macugen", "bevacizumab", "Avastin", "ranibizumab", "Lucentis", "aflibercept", "Trap-eye", "Ozurdex", "dexamethasone invitreal implant", and "clinical trial". We evaluated the quality of selected studies using Cochrane or Newcastle-Ottawa scale. Data were extracted and analyzed by RevMan 5.3 for Meta-analysis.
      Results  The mean difference in the mean changes of best corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters comparing DEX with anti-VEGF was 0.04[95% confidence interval (CI):-2.07~2.15; P=0.97] at 1 month, -6.98(95% CI:-10.39~-3.58; P < 0.0001) at 3 months, -12.18(95% CI:-20.34~-4.03; P=0.003) at 4 months, and -11.84(95% CI:-19.66~-4.02; P=0.003) at 6 months. A greater reduction of central retinal thickness at 6 months was observed in the anti-VEGF group than in the DEX group (mean difference 135.86 μm; 95% CI:57.07~214.64 μm; P=0.0007). The incidence of intraocular pressure increase in the DEX group was significantly higher than that in the anti-VEGF group (OR=3.54, 95% CI:1.64~7.66, P=0.001).
      Conclusions  Anti-VEGF showed better effect than DEX in improving BCVA, reducing ME, and less influence on intraocular pressure for ME secondary to RVO. Therefore, anti-VEGF may have higher efficacy and safety than DEX for this condition.
    • FullText(HTML)
    • References (31)
  • [1]
    Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia[J]. Ophthalmology, 2010, 117: 313-319.e311. DOI: 10.1016/j.ophtha.2009.07.017
    [2]
    Cekic O, Cakir M, Yazici AT, et al. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion[J]. Curr Eye Res, 2010, 35: 925-929. DOI: 10.3109/02713683.2010.496540
    [3]
    Demir M, Dirim B, Acar Z, et al. Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion[J]. Indian J Ophthalmol, 2014, 62: 279-283. DOI: 10.4103/0301-4738.105769
    [4]
    Ding X, Li J, Hu X, et al. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion[J]. Retina, 2011, 31: 838-845. DOI: 10.1097/IAE.0b013e3181f4420d
    [5]
    Fan C, Wang Y, Ji Q, et al. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion[J]. Curr Eye Res, 2014, 39: 938-943. DOI: 10.3109/02713683.2014.885533
    [6]
    Figueroa MS, Ruiz Moreno JM. BRAVO and CRUISE: ranibizumab for the treatment of macular edema secondary to retinal vein occlusion[J]. Arch Soc Esp Oftalmol, 2012, 87 Suppl 1: 46-53. https://www.ncbi.nlm.nih.gov/pubmed/24278989
    [7]
    Higashiyama T, Sawada O, Kakinoki M, et al.Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion[J]. Acta Ophthalmol, 2013, 91: 318-324. DOI: 10.1111/j.1755-3768.2011.02298.x
    [8]
    Lee K, Jung H, Sohn J. Comparison of injection of intravitreal drugs with standard care in macular edema secondary to branch retinal vein occlusion[J]. Korean J Ophthalmol, 2014, 28: 19-25. DOI: 10.3341/kjo.2014.28.1.19
    [9]
    Bezatis A, Spital G, Hohn F, et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up—the SOLO study[J]. Acta Ophthalmol, 2013, 91: e340-e347. DOI: 10.1111/aos.12020
    [10]
    Ferrini W, Ambresin A. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting[J].Klin Monbl Augenheilkd, 2013, 230: 423-426. DOI: 10.1055/s-0032-1328388
    [11]
    Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion[J]. Ophthalmology, 2010, 117: 1134-1146.e3. DOI: 10.1016/j.ophtha.2010.03.032
    [12]
    Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118: 2453-2460. DOI: 10.1016/j.ophtha.2011.05.014
    [13]
    Kuppermann BD, Haller JA, Bandello F, et al. Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion[J]. Retina, 2014, 34: 1743-1749. DOI: 10.1097/IAE.0000000000000167
    [14]
    Schmitz K, Maier M, Clemens CR, et al. Reliability and safety of intravitreal Ozurdex injections. The ZERO study[J]. Ophthalmologe, 2014, 111: 44-52. DOI: 10.1007/s00347-012-2737-2
    [15]
    Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant[J]. Ophthalmology, 2012, 119: 1190-1198. DOI: 10.1016/j.ophtha.2011.12.028
    [16]
    Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March, 2011][M/OL]. The Cochrane Collaboration, 2011. http://handbook.cochrane.org.
    [17]
    Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta analyses[EB/OL]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
    [18]
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. J Clin Epidemiol, 2009, 62:1006-1012. DOI: 10.1016/j.jclinepi.2009.06.005
    [19]
    Guignier B, Subilia-Guignier A, Fournier I, et al.Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion[J].Ophthalmologica, 2013, 230: 43-49. DOI: 10.1159/000350812
    [20]
    Chiquet C, Dupuy C, Bron AM, et al. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study[J]. Graefes Arch Clin Exp Ophthalmol, 2015, 253:2095-2102. DOI: 10.1007/s00417-015-2947-9
    [21]
    Novartis(Novartis Pharmaceuticals). Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (COMRADE-B). NCT01396057[EB/OL].(2014-08-04)https://clinicaltrials.gov/ct2/show/NCT01396057?term=NCT01396057&rank=1.
    [22]
    Novartis(Novartis Pharmaceuticals). Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (COMRADE-C).NCT01396083[EB/OL].(2015-02-25)https://clinicaltrials.gov/ct2/show/NCT01396083?term=NCT01396083&rank=1.
    [23]
    Argon laser photocoagulation for macular edema in branch vein occlusion.The Branch Vein Occlusion Study Group[J]. Am J Ophthalmol, 1984, 98: 271-282. DOI: 10.1016/0002-9394(84)90316-7
    [24]
    Central Vein Occlusion Study Group M. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion.The Central Vein Occlusion Study Group M report[J]. Ophthalmology, 1995, 102: 1425-1433.
    [25]
    Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion[J].Curr Opin Ophthalmol, 2012, 23:175-181. DOI: 10.1097/ICU.0b013e3283524148
    [26]
    Edelman JL. Differentiation introcular glucocorticoids[J]. Ophthalmologica, 2010, 224(Suppl 1):25-30.
    [27]
    Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase Ⅲ study[J].Ophthalmology, 2011, 118:2041-2049. DOI: 10.1016/j.ophtha.2011.02.038
    [28]
    Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study[J]. Am J Ophthalmol, 2013, 155:429-437. DOI: 10.1016/j.ajo.2012.09.026
    [29]
    Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study[J]. Ophthalmology, 2014, 121: 202-208. DOI: 10.1016/j.ophtha.2013.08.012
    [30]
    Fialho SL, Bahar-Cohen F, Silva-Cunha A. Dexamethasone loaded poly(epsiloncaprolactone) intravitreal implnats: a pilot study[J].Eur J Pharm Biopharm, 2008, 68:637-646. DOI: 10.1016/j.ejpb.2007.08.004
    [31]
    Bakri SJ, Omar AF, Iezzi R, et al. Evaluation of multiple dexamethasone intravitreal implants in patients with macular edma associated with retinal vein occlusion[J]. Retina, 2016, 36:552-557. DOI: 10.1097/IAE.0000000000000750
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (197) PDF downloads (13) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close